Interleukin-23: as a drug target for autoimmune inflammatory diseases

The Myeloid Differentiation Factor 88 (MyD88) Is Required for CD4+ T Cell Effector Function in a Murine Model of Inflammatory Bowel Disease

(2014) M. Fukata et al.   JOURNAL OF IMMUNOLOGY

IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage

(2014) G. L. Stritesky et al.   JOURNAL OF IMMUNOLOGY

Novel approach for interleukin-23 up-regulation in human dendritic cells and the impact on T helper type 17 generation

(2011) Qunwei Wang et al.   IMMUNOLOGY

Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis

(2010) G. Tonel et al.   JOURNAL OF IMMUNOLOGY

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

(2010) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-23 production in dendritic cells is negatively regulated by protein phosphatase 2A

(2010) J. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reconciling id, ego, and superego within interleukin-23

(2009) Cristina M. Tato et al.   IMMUNOLOGICAL REVIEWS

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

(2009) L. van der Fits et al.   JOURNAL OF IMMUNOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes

(2009) Michael Goldberg et al.   MOLECULAR IMMUNOLOGY

Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis

(2009) K. Nistala et al.   RHEUMATOLOGY

Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis

(2008) F Brentano et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion

(2008) C. Chizzolini et al.   BLOOD

Induction, function and regulation of IL-17-producing T cells

(2008) Kingston H. G. Mills   EUROPEAN JOURNAL OF IMMUNOLOGY

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation

(2008) Wenjun Ouyang et al.   IMMUNITY

Induction of lymphotoxin-α by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70

(2008) Malabendu Jana et al.   IMMUNOLOGY

Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells

(2008) Ivana Stojanović et al.   IMMUNOLOGY

Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells

(2008) Franca Gerosa et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Structure of Interleukin-23 Reveals the Molecular Basis of p40 Subunit Sharing with Interleukin-12

(2008) Patrick J. Lupardus et al.   JOURNAL OF MOLECULAR BIOLOGY

Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody

(2008) Brian M. Beyer et al.   JOURNAL OF MOLECULAR BIOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

Inducible IL-23p19 expression in human microglia via p38 MAPK and NF-κB signal pathways

(2007) Yonghai Li et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY